IFG
MTNB icon

Investors Financial Group’s Matinas BioPharma MTNB Stock Holding History

Investors Financial Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-67
Closed -$51K – 115
2021
Q4 		$51K Sell
67
-40
-37% -$32.1K 0.02% 211
2021
Q3 		$104K Buy
107
+47
+78% +$30.4K 0.06% 195
2021
Q2 		$35K Hold
60
– – 0.02% 202
2021
Q1 		$47K Buy
60
+20
+50% +$20.1K 0.03% 191
2020
Q4 		$41K Hold
40
– – 0.03% 163
2020
Q3 		$23K Buy
40
+27
+208% +$16.1K 0.02% 158
2020
Q2 		$8K Buy
+13
New +$7.48K 0.01% 149

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arkadios Wealth Advisors
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $67.3M AUM 9.93% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

Investors Financial Group's MTNB Position: Q1 2022 in Review

Investors Financial Group sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 67 shares — an estimated $51K sold.

Investors Financial Group first reported a position in MTNB in Q2 2020 and held it in 7 quarters. The position peaked at $104K in Q3 2021. 55 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

  • Investors Financial Group reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
  • Investors Financial Group sold 67 Matinas BioPharma shares in Q1 2022, an estimated $51K.
  • Investors Financial Group first reported a position in Matinas BioPharma in Q2 2020 and held it in 7 quarters.
  • Investors Financial Group's Matinas BioPharma position peaked at $104K in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on Investors Financial Group's 13F filing for Q1 2022.